Dealmakers newsletter: October 2008
Welcome to October's edition of the Dealmakers newsletter from CurrentPartnering.
Sponsored by: Intralinks | EuroPLX | DMS Data Systems
If not already signed up to receive our newsletters, do so here.
In this issue:
- Editor's corner
- NEW Partnering roundup
- Networks adds Plaxo
- New partnering reports
- In the news - October 2008
- New best practice articles
- Forthcoming events
- Scorecards - newly updated with latest deals
- People on the move
- Partnering resources: Online partnering
- Glossary of partnering terms
The October issue of Dealmakers is sponsored by:
Partnering in Biopharma report series
With the credit crunch continuing to bite into the biopharma sector, there is no better time to obtain cost effective partnering support and advice.
CurrentPartnering's Partnering in Biopharma report series provides the reader with up to date advice and insight into the actual partnering deals previously entered by your propsective partners.
Deal type reports: Co-promotion, co-marketing, M&A, manufacturing, supply, distribution
Stage of development reports: Discovery, Preclinical, Clinical stage
Bigpharma focus reports: Partnering with Bigpharma, Bigpharma Partnering Agreements, plus over 50 single company partnering guides
For further details visit the reports section
EDITOR'S CORNER
Continuing this month, our timely roundup of partnering related articles across the web. Each article focuses on a topic of particular interest to the biopharma industry including financing, IP, M&A, partnering.
NETWORKS continues to grow and we have recently added a new channel from Plaxo - join now - Networks
October has seen the ImClone acquisition story explode into life with Lilly agreeing a $6.5 billion price to acquire the biotech company from under the noses of BMS. There are also plenty of new partnering deals to report despite the ongoing financial crisis.
We have been busy in our report publishing activities - latest reports are now available
Discovery stage partnering agreements with biopharma
The report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies.
The report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.
We have also made available Partnering Guides for each of the top 50 bigpharma companies. You can view a list of companies here.
You can also view the leading deals so far this year in our updated Scorecards.
Until next time - happy dealmaking!
- Steve Poile
NEW - PARTNERING ROUNDUP
The following are a list of articles of interest to business developers - updated monthly in this newsletter links working at time of publication
Landmark study reports breakdown in biotech patent system
TheScientist 2008 Life Science Salary Survey
Managing Pharma’s Dilemma: MacAllister Explains
Novartis plans no big buys, to keep Roche stake
Big Pharma set for costly shopping spree
Pharma finds deals aren't so easy
Standstill Agreements Limit Potential Buyout Deals
Collaboration deals present options for young biotech firms
Biotechs scavenge for funds as IPO well stays dry
Economic crisis rips biotech's bargaining position
NYSE Euronext seen mulling easier biotech IPOs
Big pharma need to manage working capital better – E&Y
NETWORKS - Now includes Plaxo
Networks facilitates the connecting of business developers in biopharma through the use of social networkings tools - including LinkedIn, Plaxo, Facebook, Twitter and GoogleMaps.
To join or participate in CurrentPartnering's Network tools, just click on the link below for further details Networks - join now!
NEW PARTNERING REPORTS
Discovery Stage Partnering Agreements in Biopharma
The Discovery Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies Discovery Stage Partnering Agreements in Biopharma report.
Partnering with Bigpharma
The report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies Partnering with Bigpharma
Individual Partnering Guides for each of the top 50 bigpharma companies - just $395 each
Pfizer - GlaxoSmithKline - Sanofi-Aventis - Novartis - AstraZeneca - Johnson & Johnson - Merck - Roche - Wyeth - Eli Lilly - Bristol-Myers Squibb - Mayer - Abbott - Amgen - Boehringer-Ingelheim - Schering-Plough - Takeda - Genentech - Teva - Novo Nordisk - Astellas - Daiichi Sankyo - Merck KGaA - Eisai - Otsuka - Servier - UCB - Baxter - Nycomed - Solvay - Gilead - Genzyme - Forest - Menarini - Allergan - Mitsubishi Tanabe - Chugai - Procter & Gamble - Ratiopharm - CSL - Barr - Alcon - Mundipharma - Shire - Biogen Idec - Stada - King - Lundbeck - Activis - Watson
Full list of top 50 companies covered
Clinical Stage Partnering Agreements in Biopharma
The Clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the clinical stage partnering agreements entered into by the worlds leading biopharma companies Clinical Stage Partnering Agreements in Biopharma report.
Co-promotion & Co-marketing Agreements in Biopharma
The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies Co-promotion & Co-marketing Agreements in Biopharma
Also:
- Manufacturing and Supply Agreements in Biopharma
- Distribution Agreements in Biopharma
- Bigpharma Partnering Agreements
- Merger and Acquisition Agreements in Biopharma
- Practical Guide to Finding Partners in Biopharma
IN THE NEWS
The latest partnering developments - October 2008:
October has alrady seen a number of new partnership and M&A accouncements, including:
- Eli Lilly to buy ImClone Systems for $6.5 billion
- Covance and Eli Lilly in 10-year strategic R&D collaboration
- Opko Health acquires worldwide ophthalmic rights to Teva
- Genentech, Glycart and Roche in collaboration agreement
- Eli Lilly and Deciphera in licensing and collaboration deal
- Meda acquisition of product portfolio from Roche completed
NEW BEST PRACTICE ARTICLES
IP Financing: the Ten Commandments
Ten Commandments’ that are applicable in almost every case. The advice they offer is only the beginning, though: they are no substitute for careful thought, strategic financial planning or professional advice
The Challenge of IP Financing
A growing share of commerce in today’s global information economy revolves around IP assets rather than the physical commodities that dominated the industrial age
Intellectual Property Financing – An introduction
IP financing, or the use of IP assets (trade marks, design rights, patents and copyright) to gain access to credit, is gaining increasing attention in IP circles
FORTHCOMING EVENTS
Here is our suggested partnering events for the fall of 2008.
Therapeutic Area Partnerships 2008
Philadelphia, PA, USA - November 3-5, 2008
Windhover Information's 3rd Annual Therapeutic Area Partnerships is the industry's most targeted, efficient, and strategic-level partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic and Neuroscience Therapeutic Area Partnerships 2008
Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements
American Conference Institute's annual conference continues its tradition this year by bringing together key industry leaders and government representatives in order to discuss the critical issues impacting this ever changing landscape Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements
BioEurope 2008
Mannheim, Germany - November 17-19, 2008
The 14th annual BIO-Europe event is the world’s largest dedicated biotechnology partnering conference BioEurope 2008
EuroPLX 38 Valetta
Barcelona, Spain - November 24-25, 2008
Collaborative Agreements in Prescription Drugs from Clinical Candidates to Value Added Generics - Development, Licensing, Marketing and Distribution EuroPLX 38 Valetta
Pharma Business Strategies for Biomarkers
San Francisco, CA, USA, December 11-12, 2008
Top business development executives talk about how biomarkers are driving value in today’s dealmaking environment Pharma Business Strategies for Biomarkers
SCORECARDS
Our scorecards have been updated with the latest deals to break into our most valuable deal rankings.
In addition, we have updated our top 25 bigpharma partnering activity scorecard for deals up to end September 2008.
- Partnering Top 20 - 2008
- Partnering Top 20 - 2007
- Partnering since 2000
- M&A Top 20 - 2008
- M&A Top 20 - 2007
- M&A since 2000
- Bigpharma Top 25 partnering - 2008
PEOPLE ON THE MOVE
The following people have been reported on the move during the weeks of September/October 2008:
Steven Bernitz, Sven Rohmann, Tammy Mullarky, Fritz Rudert, Marc Silver, Georgia Erbez to name just a few
read more about the latest people on the move
If you have news about a business development executive who is on the move - let us know
PARTNERING RESOURCES: ONLINE PARTNERING
Numerous online websites exist to support finding and securing partners, whether you are a corporation of academic organization - Online partnering
GLOSSARY: UPDATED PARTNERING TERMS
The most recent addition is SPC or Supplementary Protection Certificate - a concession granted to pharma to extend protection under a patent more details
Full Glossary can be accessed here
Do you have specific glossary terms that you would like to see in our website? Give us your ideas here
CurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers
Advertizing and sponsorship
CurrentPartnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.
or contact us to discuss your requirements.
Steve Poile, Editor
Web: http://www.CurrentPartnering.com
Mail: CurrentPartnering, Allanmere House, 6 Hobgate, York, YO24 4HF, United Kingdom
Tel: +44 7896 656732
Fax: +44 8703 305993
Scorecard Index
Deal term reports
The information you provide is excellent and we look forward to doing more business with you in the future
...You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date...
CurrentPartnering Reports
The latest reports on best practise for dealmakers available from CurrentPartnering
Quick links
Term of the week...
Heads of agreement A pre-agreed document that outlines the key elements and structure of the planned deal.